Debio 0932 Inhibitor

Name: Debio 0932 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754774
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754774

Debio 0932 is an orally active inhibitor of HSP90 (IC50s: 100 and 103nM for HSP90alpha and HSP90beta, respectively). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Debio 0932, Inhibitor

Full Product Name

Debio 0932

Product Synonym Names

CUDC-305

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

442.58

Solubility

DMSO: 33mg/mL (74.56mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C22H30N6O2S

SMILES

NC1=NC=CC2=C1N=C(SC3=C(N(C)C)C=C(OCO4)C4=C3)N2CCNCC(C)(C)C

CAS Number

1061318-81-7

Target & IC50

HSP90alpha: ic50 100nM
HSP90beta: ic50 103nM

In Vitro

Debio 0932 is able to cross the blood-brain barrier. Debio 0932 (30mg/kg, p.o.) exhibits favorable pharmacokinetic profiles in tumor-bearing nude mice. Debio 0932 (80mg/kg, p.o.) significantly alleviates psoriasis by day 11 and decreases epidermal thickness in psoriasis xenograft transplantation model [2]. Debio 0932 (160mg/kg, p.o.) causes degradation of HSP90 client proteins, suppresses tumor growth, and also prolongs survival in various animal models of U87MG glioblastoma. Debio 0932 (160mg/kg, p.o.) also promotes antitumor activity in the erlotinib-resistant H1975 subcutaneous tumor model. Debio 0932 (40, 80, or 160mg/kg, p.o.) also dose-dependently inhibits tumor growth in the U87MG s.c. tumor model by every-other-day (q2d) dosing [1]. Debio 0932 (80, 120, and 160mg/kg, p.o.) displays dose-dependent inhibition of tumor growth in the H1975 subcutaneous tumor model [3].

Product Categories/Family for Debio 0932, inhibitor

Cytoskeletal Signaling; HSP; Metabolism

Product References and Citations for Debio 0932, inhibitor

Bao R, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 2009 Jun 15;15(12):4046-57.
Bao R, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 2009 Jun 15;15(12):4046-57.
Stenderup K, et al. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol. 2014 Nov;94(6):672-6.
Stenderup K, et al. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol. 2014 Nov;94(6):672-6.
Bao R, et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 2009 Dec;8(12):3296-306.
Bao R, et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 2009 Dec;8(12):3296-306.

Other Notes

Small volumes of Debio 0932, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Debio 0932 purchase

MBS5754774 is an inhibitor targeting Debio 0932.